by Joris Van Arensbergen | Dec 11, 2025 | Blog, News, SURE Technology
Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the...
by Joris Van Arensbergen | Dec 4, 2025 | Blog, News, SURE Technology
Annogen is excited to confirm our attendance at the upcoming Advanced Therapies Congress, scheduled for March 17th – 18th, 2026, at ExCeL London! We invite you to schedule a meeting to learn more about how Annogen can support your research and development efforts. Our...
by Joris Van Arensbergen | Dec 4, 2025 | Blog, FACE technology, News, Poster
Annogen is thrilled to announce our participation in the upcoming Plant & Animal Genome (PAG 33) conference, taking place from January 10-14, 2026, in beautiful San Diego, California! As the trusted partner for advanced crop and animal engineering, we are eager to...
by Joris Van Arensbergen | Sep 17, 2025 | Blog, FACE technology, News, SURE Technology
Annogen is launcing its proprietary SuRE™ platform, which is used for functional annotation and improvement of promoters and enhancers, for applications in crop engineering. The powerful platform provides a massive-scale “blueprint” of a crop’s...
by Joris Van Arensbergen | Sep 17, 2025 | Blog, News, SURE Technology
Annogen is thrilled to announce our participation in the upcoming European Society of Gene and Cell Therapy (ESGCT) conference, taking place from October 7th to 10th in beautiful Seville, Spain! As a leading force in advanced therapy innovation, we are eager to...
by Joris Van Arensbergen | Sep 17, 2025 | Blog, News, SURE Technology
Barcelona, The Netherlands – September 10, 2025 Lentitek and Annogen join forces to improve the quality and safety of T-cell therapies. This collaboration, jointly announced at the CGTI Leadership Summit today, aims to improve lentivirus-based CAR-T therapies by...
